ONELLIS STANFORD: Open Payments
NPI 1922237452 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$930 in 41 payments from 15 companies in 2025. Trend: 2023 $228 · 2024 $655 · 2025 $930
Food & beverage: $923Education: $7
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 10 | $365 |
| Sumitomo Pharma America, Inc. | 6 | $103 |
| Novo Nordisk Inc | 5 | $96 |
| Merck Sharp & Dohme LLC | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 3 | $46 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $45 |
| ABBVIE INC. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Abbott Laboratories | 2 | $34 |
| Corcept Therapeutics | 1 | $22 |
Products named: EVENITY, GEMTESA, Ozempic, GARDASIL 9, OTEZLA, Kerendia, CAPLYTA, FREESTYLE LIBRE.
Industry payments across MS — which companies pay providers there.
